Companies › Basilea Pharmaceutica
5 active drug programs in 8 registered trials: 6 Phase 1, 2 Phase 3; Other, Genitourinary, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| fosmanogepix GPI-anchored wall transfer protein 1 inhibitor | IPCS1, HMG1, FKS1 | Phase 3 | Candidemia; Invasive Mold Infections; Healthy Adult Participants; End Stage Renal Disease on Dialysis | Mar 2027 |
| Ceftibuten Bacterial penicillin-binding protein inhibitor | FTSZ | Phase 1 | Healthy Volunteer | Dec 2026 |
| Ceftibuten-ledaborbactam etzadroxil Beta-lactam antibiotic combined with beta-lactamase inhibitor | FTSZ | Phase 1 | Healthy Volunteer | Dec 2026 |
| Ledaborbactam etzadroxil Beta-lactamase inhibitor | FTSZ | Phase 1 | Healthy Volunteer | Dec 2026 |
| BAL2420 Antibacterial agent | – | Phase 1 | Healthy | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06733675 | Ceftibuten-ledaborbactam etzadroxil | Phase 1 | Healthy Volunteer | Other | Dec 2026 |
| NCT06733675 | Ledaborbactam etzadroxil | Phase 1 | Healthy Volunteer | Other | Dec 2026 |
| NCT06733675 | Ceftibuten | Phase 1 | Healthy Volunteer | Other | Dec 2026 |
| NCT07881224 | fosmanogepix | Phase 1 | Healthy Adult Participants | Other | Mar 2027 |
| NCT07500181 | BAL2420 | Phase 1 | Healthy | Other | Jun 2027 |
| NCT07916181 | fosmanogepix | Phase 1 | End Stage Renal Disease on Dialysis | Genitourinary | Nov 2027 |
| NCT05421858 | fosmanogepix | Phase 3 | Candidemia | Infectious disease | Jan 2028 |
| NCT06925321 | fosmanogepix | Phase 3 | Invasive Mold Infections | Infectious disease | Feb 2028 |
Shanghai Ark Biopharmaceutical Shanghai Argo Biopharmaceutical Tortugas Neuroscience Daewoong Pharmaceutical Sirnaomics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.